Kornimate/medical-research-clean huggingface dataset:
changes of the infusion rate in insulin pump treatment

Conditions: Diabetes

Summary: a pharmacokinetic study of insulin pump treatment using insulin aspart. the study consist of three different periods a, b and c where a constant the insulin infusion rate is given during the periods. in period b and c will the infusion start with a bolus. it will be investigated if a steady state of insulin will be obtained faster in period b and c then a.

a pharmacokinetic study of insulin pump treatment using insulin aspart. the study consist of three different periods a, b and c where a constant the insulin infusion rate is given during the periods. each period will last 12 hours and blood will be drawn to measure absorbed insulin aspart. during period a will a constant the infusion rate of insulin be given. in period b and c will there at the start of the constant infusion rate be given a bolus. the bolus in period c is calculated on the basis of the results in period b, therefore will all participants experience period c last where as period a and b is randomized cross-over. period c is written in the protocol as optional and it is evaluated after period a and b if period c will be performed. the hypothesis is that steady state of insulin will be obtained faster in period b and c than a.

Eligibility criteria:
inclusion criteria: * informed consent * healthy volunteer * men and women between ≥18 and \<50 years * women in the child-bearing age should be sufficient protected against pregnancy (use birth control pill or intrauterine device or be sterilized or hysterectomized) * bmi between 18-30 kg/m\^2 (both included) exclusion criteria: * suspected or known allergy against the drug used in the study or similar drugs * previous history of endocrinology disease (including diabetes mellitus) * suspected or known alcohol- or drug abuse * any disease influencing the study, evaluated by the investigator * pregnancy, breast-feeding or the wish of becoming pregnant during the study period. furthermore women in the child bearing age not sufficient protected against pregnancy (sufficient is: use of birth control pill or intrauterine device or be sterilized or hysterectomized) * participation in other research projects during the last 3 months before this project

Keywords: insulin pump treatment csii absorption insulin aspart
esophageal sparing intensity-modulated radiation therapy (imrt) for locally-advanced thoracic malignancies

Conditions: Non Small Cell Lung Cancer; Small Cell Lung Cancer; Thymoma; Thymus Neoplasms

Summary: hypothesis 1- using imrt, the radiation therapy (rt) dose can be safely escalated from 58 gy to 74 gy given as 6 fractions/week with concurrent chemotherapy. hypothesis 2- esophageal motion can be used to customize planning organ at risk volumes. hypothesis 3- biological predictors of acute esophagitis can be used to identify patients at high risk of developing esophageal toxicity from radiation therapy and chemotherapy.

prospective phase i study designed to determine the maximum tolerated dose of radiation therapy given in an accelerated fashion (2 gy/fraction, 6 fractions/week) with concurrent chemotherapy. intensity-modulated radiation therapy (imrt) will be utilized to spare the esophagus. all patients on the dose escalation study will participate in additional assessments evaluating esophageal motion and esophageal toxicity from radiation therapy.

Eligibility criteria:
inclusion criteria: * histologic documentation of one of the following thoracic malignancies: * non-small cell lung cancer (stage iii or x (recurrent) with disease confined to local/regional sites) * small cell lung cancer (stage ii-iii) * thymoma (unresectable) * thymic carcinoma (unresectable) * eastern cooperative oncology group (ecog) performance status 0-1 * weight loss \< 10% in preceding 3 months prior to diagnosis * anc \> or = 1500 and platelet count \> or = 100,000. * creatinine clearance greater than 50 ml/min * 18 years of age or older. * negative pregnancy test in women of child-bearing potential exclusion criteria: * prior thoracic irradiation * medical contraindications to thoracic irradiation

Keywords: non small cell lung cancer small cell lung cancer thymoma unresectable thymic carcinoma unresectable
freshair4life: building the case for action

Conditions: Tobacco Use; Pollution; Exposure; Non-communicable Disease

Summary: the goal of this observational study is to understand the burden and determinants of tobacco use and air pollution (ap) exposure among mid- to late adolescents in greece, the kyrgyz republic, pakistan, romania, and uganda. this context-specific knowledge will be crucial for selecting, adapting, and implementing preventive interventions in the next phase of the project. the main questions the investigators aim to answer are: * what is the perceived burden of tobacco use and ap exposure among adolescents? * what are the contextual drivers and behavioral determinants contributing to (prevention of) these risk factors? * how do the dynamics between stakeholders influence prevention efforts? in this study, data will be collected through interviews, focus group discussions, photovoice, document analysis, observations, personal exposure monitoring, and questionnaires.


Eligibility criteria:
inclusion criteria: * adolescents: mid- to late-adolescents (14 to 21 years) within the target population; * family members: relatives in the first or second degree of (not necessarily participating) adolescents; * providers: any relevant stakeholder that is connected to adolescents through profession (e.g. school teacher, youth worker) and/or providers of (public) healthcare; * stakeholders: any relevant stakeholder with either a specific expertise, in-depth knowledge or overall overview on the subject, and in direct contact with the community (e.g. community member/leader, policy maker). due to the community- and individual-level focus of this research, individuals associated with the tobacco industry are deliberately not included as stakeholders. exclusion criteria: - people living outside the target area or not in direct contact with the target population.

Keywords: implementation studies mixed-methods participatory research
lactobacillus preparation on the incidence of diarrhea

Conditions: Diarrhea; Death; Pneumonia

Summary: the purpose of this trial is to clarify the impact of lactobacillus preparation on the incidence of diarrhea in icu-admitted patients. almost all patients in icu are treated with antibiotics for the effective control of various infections. however, antibiotics-associated diarrhea is another matter of concern. many previous studies were proved that the use of probiotic lactobacillus preparation can reduce antibiotics-associated diarrhea in ward-admitted patients. in this study, we are planning to perform a similar study in severely ill patients in icu.


Eligibility criteria:
inclusion criteria: * all patients admitted in intensive care unit * age more than 19 exclusion criteria: * diarrhea occurence within 1 week of icu admission * recent history of probiotics use (within 1 month) * gi obstruction * history of abnormal symptoms and sign for the probiotics use (rash, edema, sepsis, etc.) * immunocompromized patients

Keywords: probiotics diarrhea intentive care units
comparison of outcomes between biceps tenotomy and tenodesis in the treatment of the long head of the biceps pathology

Conditions: Chronic Refractive Bicipital Pain

Summary: the purpose of the study is to determine what the different outcomes are for biceps tenodesis and tenotomy in the treatment of the long head of the biceps pathology.


Eligibility criteria:
inclusion criteria: * patient with chronic refractive bicipital pain exclusion criteria: -

Keywords: biceps tenodesis biceps tenotomy biceps tendonitis biceps inflammation shoulder surgery
cold application on pain during chest tube removal

Conditions: Chest Tube Removal

Summary: abstract objectives: use of analgesics is the most common method to alleviate the pain induced by chest tube removal (ctr), but patient response to medication can vary and may not be achieved complete relaxation. this study was to determine the effectiveness of cold application in combination with standard analgesic administration before ctr on ctr-induced pain. methods: a prospective, randomized, single-blind, placebo sham-controlled study was conducted. in addition to the same routine care, subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before ctr, whereas subjects in the placebo sham group (n = 30) received tap water packs. numerical rating scale was used to measured pain intensity before, immediately after, and 10 minutes after ctr.


Eligibility criteria:
inclusion criteria: * (a) age greater than 20 years, (b) single chest-tube insertion, (c) first-time insertion of the chest tube, (d) ability to verbally report pain, (e) body mass index of \< 30 kg/m2, and (f) normal vital signs. exclusion criteria: * cold urticaria
clinical signs and activity limitations associated with dural ectasia in patients with marfan disease

Conditions: Marfan Syndrome

Summary: primary outcome is to compare the frequency and clinical features of spinal symptoms between marfan patients with dural ectasia (cases) and those without (controls). 1. / frequency of orthostatic headaches 2. / frequency of low back pain due to orthostasis 3. / frequency of low back pain during vasalva maneuvers 4. / frequency of lumbar claudication 5. / frequency of root claudication secondary outcomes are to compare activity limitations, quality of life and intensity of low back and radicular pain between marfan patients with dural sac ectasia (cases) and those without (controls). 1. / average intensity of back pain measured on a self-administered digital scale (0 = no pain and 100 = maximum pain) 2. / average intensity of radicular pain measured on a self-administered digital scale (0 = no pain and 100 = maximum pain) 3. / activity limitations specific to the lumbar spine measured using the self-administered oswestry disability index questionnaire (odi, 0 = no limitations and 100 = maximum limitations) 4. / physical component of quality of life measured using the physical component of the self-administered questionnaire 12-item short form health survey (sf-12, 9.95 = worst quality of life imaginable, 70.02 = worst quality of life imaginable ) 5. / mental component of the quality of life measured using the mental component of the sf-12 self-administered questionnaire (5.89 = worst quality of life imaginable, 71.97 = worst quality of life imaginable)

marfan's disease is a rare condition. clinical phenotypes are heterogeneous. among the abnormalities of the spine, dural ectasia is common with a prevalence of 66%. this is a major sign of ghent's diagnostic criteria. to our knowledge, the clinical and functional signs associated with dural sac ectasia have never been described with precision. only a few uncontrolled case series have been published. this is the case of the study by foran and colleagues published in the american journal of genetics in 2005 which included 22 patients with marfan disease with dural ectasia questioned about their symptoms and quality of life. we hypothesize the existence of a clinical and functional spinal phenotype specific to dural ectasia in patients with marfan disease.

Eligibility criteria:
inclusion criteria: * marfan disease according to the ghent criteria revised in 2010 * patients followed at the cnmr in bichat * adults ≥18 years old and ≤ 55 years old (to limit the incidence of degenerative lumbar pathologies) * patient not opposing the research * mastery of the french language exclusion criteria: * history of lumbar surgery \<1 year * specific pathologies of the spine (tumor, infection, trauma, fracture, inflammatory rheumatism) * inability to write, read or speak french * cognitive or behavioral problems making assessment impossible * patients receiving ame * patients under tutorship or curatorship

Keywords: marfan's disease dural ectasia clinical signs intracranial hypotension low back pain activity limitation
hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% for ocular surface disease in glaucoma

Conditions: Ocular Surface Disease; Glaucoma

Summary: to study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.


Eligibility criteria:
inclusion criteria: * osdi \> or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm. exclusion criteria: * age below 18 yo * active infectious corneal disease * post penetrating keratoplasty or glaucoma drainage device * known allergy to medication * lactation , pregnant
elevate to alleviate evidence based study

Conditions: Leg Edema; Venous; Return (Anomaly); Leg Elevation

Summary: venous return in the circulatory system of lower limbs results from the interaction of several mechanisms, and reflects the balance between blood inflow and outflow. blood outflow improves during sleeping because of the lying position especially with leg elevation. in fact, patients with chronic venous disease (cvd) improve leg symptoms in lying position and with leg elevation. the aim of this study is to evaluate the level of comfort of hospital inpatients, without cvd, if they lie with a moderate leg elevation during hospital stay.

the venous system makes the blood return to the heart with low-pressure and slow-velocity flow, within the venous system. venous return results from the interaction of diverse mechanisms, such a central pump (respiratory cycle and the heart), a pressure gradient, a peripheral venous muscular pump, and the veins valvular system. therefore, the venous volume in the lower limb is the result of the interaction between these mechanisms and reflects the balance between blood inflow and outflow. blood outflow improves during sleeping because of the lying position and, in this position, even more with leg elevation. in fact, it is known patients with chronic venous disease (cvd) improve leg symptoms in lying position and with leg elevation. the aim of this study is to evaluate the level of comfort of hospital inpatients, without cvd, if they lie with a moderate leg elevation during hospital stay. unselected patients with a hospital stay of at least seven days will be recruited and random assigned to two groups of patients: group a, that will lie in their hospital bed with a moderate leg elevation (between 15 and 30 degrees). group b, that will lie in their hospital bed without leg elevation. all patients will undergo echo duplex scanning of vascular system of lower limbs to exclude any vascular disease. for every patient complete demographic and comorbidity data will be collected. every single the day, the following parameters will be retrieved for each patient: ankle and calf diameters, heart rate, blood pressure, breath frequency, body temperature, leg heaviness (rating scale 1-10), perceived leg comfort (rating scale 1-10), hours of night sleep (number).

Eligibility criteria:
inclusion criteria: * every hospital inpatient with at least 7 hospital stay. exclusion criteria: * patients with vascular or osteoarticular leg problems that affect or prevent leg elevation during rest.

Keywords: venous returns lower limbs leg elevation
community - the covid-19 immunity study

Conditions: COVID 19; Respiratory Synctial Virus; Influenza Virus; SARS-CoV-2 Virus

Summary: the principal aim of the community study is to investigate immune responses following sars-cov-2 infection and/or vaccination in healthcare workers and hospitalized covid-19 patients. the study aims to enroll a total of 5,000 healthcare workers and 500 covid-19 patients. all participants are enrolled at danderyd hospital in stockholm, sweden. participants will be followed every four months with blood and mucosal sampling in addition to demographic and clinical data provided by the participants and from national registries. primary outcome: - antibody responses in blood and mucosa following sars-cov-2 infection and/or vaccination secondary outcomes: * cellular immune responses following sars-cov-2 infection and/or vaccination * antibody responses in blood and mucosa following following influenza a/b infection and/or vaccination * antibody responses in blood and mucosa following following rsv a/b infection blood and mucosal samples are collected every 4 months and at tighter intervals in sub studies. pcr testing is conducted upon symptoms of respiratory infections and with regular intervals regardless of symptomatology in sub studies. participants provide detailed demographic and clinical data through a smart phone application-based questionnaire. data on infection and vaccination history is collected from national registries

the community study is designed to longitudinally follow healthcare workers and recovered covid-19 patients to assess sars-cov-2 immune responses over time. follow-ups are conducted every four months, including serum, pbmc, and mucosa (saliva and nasal secretions) samples. sub studies with additional samplings and pcr screenings are conducted with regular intervals to assess vaccine responses and correlates to protection against infection. analyses include: * quantification and characterization of antibody responses * evaluation of t and b-cell responses * rt-qpcr detection of viral infection * mucosal microbiome evaluation clinical and demographic data, including information on hospital workplace, exposure, immunosuppressive treatments or conditions, and results from sars-cov-2 rapid diagnostic tests, are collected at each follow-up through a smartphone-based app system. data on sars-cov-2 infections and vaccinations are obtained from national registries. in addition, data from home based pcr-screenings are continuously being monitored for sars-cov-2, influenza and rsv infections. all samples are stored in biobank sweden.

Eligibility criteria:
inclusion criteria: * health care workers: employment at danderyd hospital at time of enrollment * covid-19 patients: admitted to danderyd hospital with confirmed sars-cov-2 infection at time of enrollment exclusion criteria: * no exclusion criteria

Keywords: covid-19 mucosal immunity pandemic vaccination secretory iga
carpal tunnel release effects on median nerve perfusion

Conditions: Carpal Tunnel Syndrome

Summary: this study aims to examine the effect of carpal tunnel release on blood flow to the median nerve using spy scope imaging to view the perfusion to the nerve.

the study will involve patients undergoing carpal tunnel release surgery at our institution, with no change in the actual procedure performed. using the spy scope, we will measure blood flow prior to the carpal tunnel release, and again measure once carpal tunnel release has been performed, in order to compare the values. this may add roughly 15 minutes to the total procedure time, however, no steps in the actual operation will be altered or affected in any way.

Eligibility criteria:
inclusion criteria: * carpal tunnel syndrome * 18 years or older exclusion criteria: * pregnant * less than 18 years of age * allergy to iodide or iodinated contrast agents
study of the efficacy and safety of amt-101 in combination with adalimumab in subjects with ulcerative colitis (market)

Conditions: Ulcerative Colitis

Summary: randomized, placebo-controlled, double-blind, parallel-group, multicenter, phase 2a study of the efficacy and safety of oral amt-101 in combination with adalimumab in subjects with moderate to severe ulcerative colitis.

this is a randomized, placebo-controlled, double-blind, parallel-group, multicenter, phase 2a study to evaluate the efficacy and safety of oral amt-101 in combination with adalimumab in subjects with moderate to severe ulcerative colitis.

Eligibility criteria:
inclusion criteria: * male and female subjects aged 18 to 75 years. * moderate to severe uc. * eligible for humira (adalimumab) therapy. * women of childbearing potential (wocbp) must have a negative pregnancy test at screening and at the randomization visit. * written informed consent must be obtained and documented. exclusion criteria: * known gastrologic, or systemic condition that may compromise severity or diagnosis of disease. * history or current evidence of colonic or abdominal abnormalities. * prohibited therapies or procedures before the screening period as specified per protocol. * a concurrent clinically significant, serious, unstable, or uncontrolled underlying cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, might confound the study results, pose additional risk to the subject, or interfere with the subject's ability to participate fully in the study. * pregnant or lactating females. * current or recent history of alcohol dependence, illicit drug use, mental or legal incapacitation, or a history of clinically significant psychiatric disorders that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures. * unable to attend study visits or comply with procedures. * previous exposure to amt-101 or similar and known hypersensitivity to amt-101 or its excipients.

Keywords: inflammatory bowel diseases
the efficacy of transarterial chemoinfusion (tai) combine toripalimab in advanced hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: to evaluate the efficacy of tai combine toripalimab in advanced hcc.


Eligibility criteria:
inclusion criteria: * older than 18 years old and younger than 75 years; * ecog ps≤1; * proven advanced hepatocellular carcinoma according patological examination or easl/aasld diagnostic criteria; * not previous treated for tumor; * cannot accepted hepatectomy; * the lab test could meet: * neutrophil count≥2.0×109/l; * hemoglobin≥100g/l; * platelet count≥75×109/l; * serum albumin≥35g/l; * total bilirubin\<2-times upper limit of normal; * alt\<3-times upper limit of normal; * ast\<3-times upper limit of normal; * serum creatine\<1.5-times upper limit of normal; * pt≤upper limit of normal plus 4 seconds; * inr≤2.2; * sign up consent; exclusion criteria: * cannot tolerate tai or toripalimab; * known history of other malignancy; * be allergic to related drugs; * underwent organ transplantation before; * be treated before (interferon included); * known history of hiv infection; * known history of drug or alcohol abuse; * have gi hemorrhage or cardiac/brain vascular events within 30 days; * pregnancy;
tolerability of alk tree tablet

Conditions: Allergy

Summary: this trial is performed to assess the tolerability of the alk tree tablet in patients with birch pollen induced allergy


Eligibility criteria:
inclusion criteria: * a clinical history of birch pollen induced rhinoconjunctivitis (with or without mild to moderate asthma ) of at least two years prior to trial entry requiring symptomatic treatment during the birch pollen season. * positive skin prick test response to betula verrucosa * positive specific ige against bet v1 * fev1 ≥ 70% of predicted value exclusion criteria: * no clinical history of perennial allergic rhinitis and/or asthma caused by an allergen to which the subject is regularly exposed and sensitised * no clinical history of significant recurrent acute sinusitis (defined as 2 episodes per year for the last two years all of which required antibiotic treatment) or chronic sinusitis * no conjunctivitis, rhinitis or asthma at the screening or randomisation visit * no history of anaphylaxis, including anaphylactic food allergy, bee venom anaphylaxis, exercise anaphylaxis or drug induced anaphylaxis * no history of angioedema

Keywords: tolerability of alk tree tablet in patients with birch pollen induced allergy